Vivin C is a counter -counter drug (OTC) based on salicylic acid and vitamin C which has analgesic and antipyretic action
analgesics and antipyretics - salicylic acid and derivatives. active ingredients:
any effervescent tablet of Vivin C contains: 0.330 g acetylsalicylic acid, ascorbic acid 0,200 g.
glycine, citric acid anhydrous, sodium hydrogencarbonate, sodium benzoate
What Vivin C
Vivin C is used for the treatment of headaches and teeth, nevral gie, menstrual pain, rheumatic and muscle pain.
symptomatic therapy of feverish states and flu and cooling syndromes.
contraindications/secondary effects :
hypersensitivity to the active ingredients, to the salicylates or to any of the excipients, a trend ascertained to hemorrhages, gastropathies (e.g. gastro-duodenal ulcer), asthma.
History of gastrointestinal hemorrhage or perforation relating to previous active treatments or history of hemorrhage/recurrent peptic ulcer (two or more distinct episodes of strata ulceration or bleeding).
severe insufficiency Cardiac.
The U I know of this medicine is contraindicated in children and boys of less than 16 years old.
dose & gt; 100 mg/ During the third trimester of pregnancy
adults: 1-2 tablets if necessary up to 3-4 times beyond '.
skiglier and in half a glass of acquirer A non -carbonated one or two tablets of the medicine.
The intake of the product must take place on a full stomach.
Do not exceed the recommended doses: in particular i Elderly patients should stick to the minimal dosages above.
Do not keep at temperature above 25 degrees C. < BR>
Keep the tube very closed to protect the medicine from humidity.
warnings: < p> this medicinal specialty should not be used in children and young people of less than 16 years of age.
cases of Reye syndrome are observed in children with viral infections (in Particate chickenpox and flu-like conditions) and treated with an acesalicylic acet acid.
Reye syndrome manifests itself with persistent vomiting and signs of progressive damage of the central nervous system (torpor, up to the appearance of generalized convulsions and coma), signs of injury Hepatics and hypoglycemia.
subjects of age exceeding 70 years of et a ', especially in the presence of concomitant therapies, must use this medicine only after consulting a doctor. BR>
After three days of use at the maximum dose or after 5-7 days of continuous employment with the doctor.
It is advisable that the doctor is cons Part of patients with glucose-6-phosphate-dehydrogenase deficiency, chronic or recurring gastric and intestinal sturbs or compromised Funz Ionalita 'renal. Keep in mind that each product tablet contains about 480 mg of sodium.
use must be avoided in conjunction with fans, including selective cox-2 inhibitors.
The side effects can be eaten minimized with the use of the minimum effective dose for the shorter treatment of the shortest possible treatment that is needed to control the symptoms.
elderly: The elderly patients have an increase in the frequency of reaz adverse ions to fans, especially hemorrhages and gastrointerate extermination, which can be fatal.
gastrointestinal bleeding, ulceration and perforation: during treatment with all Fans, in any time, with or without warning symptoms or previous history of serious gastrointestinal events, gastrial ointarial bleeding, ulceration and perforation, which can be fatal, have been reported.
in the elderly e In patients with history of ulcer, especially if caragia or perforation cata complies, the risk of gastrointest hemorrhage inale, ulceration or perforation is higher with increased doses of fans.
these patients must Start the treatment with the lowest dose available.
The concomitant use of protective agents (Misoprostol or or proton pump inhibitors) must be considered for these p azienti and also for patients taking low dos I of aspirin or alt ri drugs that can increase the risk of gastrointestinal events.
patients with history of gastrointestinal toxicity, in particular the elderly, must report any unusual gastrointestinal symptom (especially gastrointestinal bleeding) in Particularly in the phases, the nitials of the treatment.
caution should be given to patients taking concomitant drugs that could increase the risk of lceration or bleeding, as oral corticosteroids, anticoagulants com and warfarin, selective inhibitors of the Reuptake of serotonin or anti -aggregating agents such as aspirin.
when hemorrhage or gastrointestinal ulcer occurs in patients taking the medicine, the treatment should be suspended. < p> NSAIDs should be administered with Ca U.works in patients with a history of gastrointestinal disease (colit and ulcerative, crohn disease) since these conditions can be ESA Cerbate.
Oucho caution in patients with a history of hypertension and /or cardiac insufficiency since, in association with the therapy with FA NS, water retention and edema have been reported. Fatali, including exfoliative dermatitis, Sin Drome of Stevens-Johnson and Epidermal toxic necrolysis, have been brought very rarely in association with the use of fans. They seem to be higher risk: the onset of the reaction occurs in most cases en tro the first month of treatment.
The medicine must be interrupted at the first appearance of skin rash, Lessons of the mucous membrane or any other sign of hypersensitivity.
corticosteroids: increased risk of ulceration or gastro hemorrhage Intestinal.
anticoagulants: fans can increase the effects of anticoagulants, such as warfarin.
anti -aggregating agents and selective inhibitors of the serotonin reuptake (SSRIS): increased risk of gastrointestinal hemorrhage.
the administration of acetylsal acid cylic, especially in the case of protracted therapy, It can enhance the side effects of the Methotrexate, the effects and secondary events of all non -steroid anti -umatics, the effect of the reducing maci the blood sugar (sulfanilurea).
precaution must be observed for The substances such as spony, furosemide and antigottous preparations, whose activity is instead reduced by the acid acetylsalicylic.
Ps, unless otherwise prescribed, the product should not be stratum in conjunction with the preparations Outputs.
gastrointestinal pathologies: the most commonly commonly observed vati events are of a gastrointestinal nature.
after administration of the pharmatale co were reported: nausea, vomiting, Diarrhea, flatulence, constipaz ion, dyspepsia, abdominal pain, ulcerative stomatitis, exacerbation and colitis and crohn disease.
peptic ulcer, also perforated gastrointestinal bleeding, which can be manifest (hematemesis , Melena) and tonight tasty, or hidden and cause sideropenic anemia.
these sanguin loves are more frequent with increasing dosage, especially and in elderly patients.
less frequently gastritis have been observed.
cardiac pathologies: edema, hypertension and heart failure have been reported in association to treatment with fans.
> Pathogs of the skin and subcutaneous tissue: bullous reactions included Sin Drome of Stevens-Johnson and epidermal toxic toxic necrolysis.
pathologies of the emolinphopoietic system: hemorrhagic syndromes (epistaxis, gingival hemorrhages, trombocytopenia, purple, purple ) with an increase in the time of bleed chin.
This effect persists for 4-8 days later The interruption of the administration of acetylsalicylic acid.
is the cause of risk of ragy hemorrine in patients undergoing surgery. (& GT; 1G) may increase emolisi in patients with deficiency of G6pd-dehydrogenase in the form of chronic emolisi.
disorders of the immune system.
reactions of hypersensitivity: Angioedema, edema of quin cke, urticaria, erythema, asthma, anaphylactic reactions.
pathologies of the nervous system: auricular hum, sensation of hearing reduction, headache, usually a sign overdose, pregnancy conditions, puerperium and perinatoli, delay in childbirth.
renal and urinary pathologies and: high doses of vitamin C (& gt; 1g) can encourage the formation of bone cal coli and uric acid in some individuals.
pregnancy and breastfeeding:
low doses (up to 100 mg/day): the clinical studies indicate that the doses up to 100 mg/day p they b should be considered safe to an employment in the obstetric field, which requires specialist monitoring. 100 mg/day up to 500 mg/day.
therefore, the recommendations below for the doses of 500 mg/day and beyond also apply to this dosage range.
doses of 500 mg/day and beyond: the inhibition of prostaglandine synthesis may affect and negatively pregnancy and/or embry/fetal development.
results of epidemiological studies suggest an increased risk of abortion and cardiac malformation and gastroschisi after the use of an inhibition and synthesis of prostaglandins, in the early stages of pregnancy.
the absolute risk of malformations cardiac had increased less than 1% of up to about 1.5%. >
In animals, the administration of prostaglandin synthesis inhibitors showed that it provokes and an increase in pre and post-system loss and embryo-fetal mortality.
in addition, an increase in incidence Of various malformations, including the cardiovascular one, it was reported in animals to which prostaglandin synthesis, Durant and the organogenetic period had been administered.
during the first and second quarter of pregnancy , acetylsalicylic acid should not be administered s and not in strictly necessary cases.
If acetylsalicylic acid is u sately from a woman waiting for conception, or during the first and sec ndo trimester of pregnancy, the dose and duration of the Devon treatment or be maintained as low as possible.
during the third trimester of pregnancy, all the inhibitors of the synthesis of prostaglandins Po are exposed the fetus A: Cardiopulmonary toxicity (with prem for acknowledges d arterial learned and pulmonary hypertension); Renal dysfunction and, which can progress in renal failure with oligo-hydroamnios: l to mother and the newborn, at the end of pregnancy to: possible extension of the bleeding time and anti-aggregating effect that can also run at very low doses; Inhibition of uterine contractions resulting late or extension of labor.
consequently, acetylsalicylic acid to doses & gt; 100 mg/day is contraindicated to ante the third trimester of pregnancy.
Medicine OTC - AIC 020096020